Abstract
During the mid 1970s, a series of case reports were published that described a strong association in women between prolonged oral contraceptive (OC) use and the appearance of liver neoplasms (1,2). Based on clinical observations, which included a few examples of regression of the liver neoplasms following cessation of OC use, and the experimental demonstrations that synthetic estrogens were not mutagenic, we hypothesized that the synthetic steroidal estrogens would be promoters of hepatocarcinogenesis (3). Subsequently, we (3) and others (2,4) demonstrated that mestranol (17-α ethynyl estradiol 3-methyl ether) and ethynyl estradiol (EE) are promoters of the appearance of preneoplastic foci and hepatocellular carcinomas in several strains of female rats. The strength of the promoting ability of these estrogens compared to several other promoters in the rat model of hepatocarcinogenesis is indicated by calculation of their promotion indices (PI), which are a function of the volume fraction of treated liver occupied by altered hepatic foci (AHF), divided by the volume fraction of control liver occupied by AHF, times the dose of promoting agent administered per week (5). The PI of phenobarbital, a classic liver promoter, was calculated to be 140, whereas the PIs for mestranol, EE, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) were calculated to be 54,000, 93,000, and 28,000,000, respectively. Thus, while the synthetic steroidal estrogens are considerably less potent than TCDD, they are approximately 400–700 times more potent than phenobarbital. In addition, both mestranol and EE treatment results in the appearance of AHF in the livers of noninitiated rats. However, studies on these two estrogens conducted in two laboratories failed to demonstrate significant genotoxic effects or ability to initiate hepatocarcinogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Molina, R, Martinez, L, Salas, O, et al (1989) Combined oral contraceptives and liver cancer. Int J Cancer 43: 254–259.
Porter, LE, Van Thiel, DH Eagon, PK, (1987) Estrogens and progestins as tumor inducers. Semin Liver Dis 7: 24–31.
Yager, J., Roebuck, BD, Paluszcyk, TL Memoli, VA (1986) Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis 7: 2007–2014.
Campen, DB, Sloop, TC, Maronpot, RR, Lucier, GW (1987) Continued development of hepatic y-glutamyltranspeptidase-positive foci upon withdrawal of 17 a-ethinyl estradiol in diethylnitrosamine-initiated rats. Cancer Res 47: 2328–2333.
Dragan, Y, Xu, Y-D, Pitot, HC (1991) Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prey Med 20: 15–26.
Ochs, H, Dusterberg, B, Gunzel, P, Schulte-Hermann, R (1986) Effect of tumor promoting contraceptive steroids on growth and drug metabolizing enzymes in rat liver. Cancer Res 46: 1224–1232.
Shi, YE Yager, JD (1989) Effects of the liver tumor promoter ethinyl estradiol on epidermal growth factor-induced DNA synthesis and epidermal growth factor receptor levels in cultured rat hepatocytes. Cancer Res 49: 3574–3580.
Standeven, AM, Shi, YE, Sinclair, JF, Sinclair, PR Yager, JD (1990) Metabolism of the liver tumor promoter ethinyl estradiol by primary cultures of rat hepatocytes. Toxicol Applied Pharmacol 102: 486–496.
Shi, YE, Yager, JD (1990) Regulation of rat hepatocyte epidermal growth factor receptor by the liver tumor promoter ethinyl estradiol. Carcinogenesis 11: 1103–1109.
Eldridge, SR, Tilbury, LF, Goldsworthy, TL, Butterworth, BE (1990) Measurement of chemically induced cell proliferation in rodent liver and kidney: a comparison of 5-bromo-2’-deoxyuridine and [3H] thymidine administered by injection or osmotic pump. Carcinogenesis 11: 2245–2251.
Bottaro, DP, Rubin, JS, Faletto, DL, et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802–804.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag New York, Inc.
About this paper
Cite this paper
Yager, J.D. (1992). Growth Stimulation and Tumor Promotion in Rat Liver by Ethynyl Estradiol and Other Estrogens. In: Li, J.J., Nandi, S., Li, S.A. (eds) Hormonal Carcinogenesis. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9208-8_18
Download citation
DOI: https://doi.org/10.1007/978-1-4613-9208-8_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4613-9210-1
Online ISBN: 978-1-4613-9208-8
eBook Packages: Springer Book Archive